Trials / Terminated
TerminatedNCT01394926
Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease
A Multi-Center, Open-Label, Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- GE Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find the optimal dose from 3 different dose levels - 0.15 mL, 0.5 mL and 1.5 mL of Optison in assessing the presence of disease of the carotid arteries when comparing pre-contrast to post-contrast ultrasound (U/S) by dose group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Optison | Optison is a sterile non-pyrogenic suspension of perflutren for IV administration. |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2011-07-15
- Last updated
- 2014-05-02
- Results posted
- 2014-04-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01394926. Inclusion in this directory is not an endorsement.